Intas launches RAZUMAB, the first biosimilar to Lucentis (ranibizumab)

Ranibizumab is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), a common degenerative condition of the eyes in the elderly

Ranibizumab is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), a common degenerative condition of the eyes in the elderly

Intas Pharmaceuticals has launched RAZUMAB, its biosimilar to Lucentis (ranibizumab). Intas is the first company globally, to develop and launch a biosimilar version of ranibizumab. RAZUMAB is manufactured under strict guidelines for sterile use in the eye and is offered as single dose vial, thus reducing the risk of contamination during use.

Ranibizumab is a therapeutic antibody fragment designed specifically for treating degenerative conditions of the eye. It blocks the production of vascular endothelial cell growth factor A (VEGF-A), a protein which when over expressed leads to abnormal blood vessel growth in the retina, that can cause leaks and vision loss.

Ranibizumab is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), a common degenerative condition of the eyes in the elderly. It is also indicated for Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy in patients with Diabetic Macular Edema and vision loss resulting from choroidal neovascularization in pathologic myopia (mCNV).

“Intas’ ranibizumab, RAZUMAB is a 100 per cent ‘Made In India’ molecule, a feat achieved by the scientists at Intas and unparalleled till date. With the mission to provide global healthcare at affordable costs, RAZUMAB will be about 25 per cent cheaper than the imported Lucentis in the hand of the patient. This would lead to an annual saving of about Rs 35,000 or more in the cost of treatment to the patient, depending on the number of injections used and the clinical condition of the patient. Our objective is to make the treatment available to a wider patient pool, that is as yet denied treatment due to high cost of imported Lucentis,” said Binish Chudgar, Vice Chairman, Intas Pharmaceuticals.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express Telegram Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.